Subsequent analyses of IMID patients who did or did not respond to treatment with anti-TNF (tumor necrosis factor), as well as more than 600 blood samples from SLE patients, supported that variable combinations of URs have the potential for personalized diagnostics and therapeutics in IMIDs. The gene discussed is TNF; the disease is systemic lupus erythematosus.